Definium’s Phase 3 Emerge Trial Shows Rapid, Durable Depression Relief & Boosts DFTX Stock by 60%
Definium’s Phase 3 Emerge trial shows a single‑dose psychedelic antidepressant boosts depression scores 8.1 points faster than placebo, sparking a 60% stock surge and analyst price‑target hikes.
3 minutes to read